Loading...

Building K Production Will Serve Peptide And Oligonucleotide Therapies

Published
02 Mar 25
Updated
26 Sep 25
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
-33.0%
7D
-4.9%

Author's Valuation

CHF 74.731.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on 26 Sep 25

Fair value Decreased 4.08%

Bachem Holding's fair value has been revised downward, primarily reflecting slight declines in both its discount rate and future P/E ratio, with the consensus analyst price target decreasing from CHF77.88 to CHF74.70. What's in the News Maintained 2026 sales guidance of over CHF 1 billion and profitability above 30%.

Shared on 01 May 25

Fair value Increased 12%

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 09 Apr 25

Fair value Decreased 4.43%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 02 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on 12 Mar 25

Fair value Increased 2.93%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.